I think we're looking at a two-phased approach here. Right now, as I said, we want to put part of the money—and it hasn't been approved yet, so I can't give you a specific number—out of the new $16 million in additional funds that we receive into clinical trials, and we are hopeful that we will receive applications for clinical trials looking at chronic cerebrospinal venous insufficiency, and a clinical trial for that. That's the first element.
The other element is to look more broadly into what are the gaps in our knowledge, particularly in terms of relationship within cerebrospinal venous drainage, but also, more broadly, cerebral-vascular problems and MS, and what are the research gaps and how, in a second phase, we can fund specifically research in those areas in which we find true gaps.
Our role is—